MedFirst Healthcare Services Inc

The company's capital structure is characterized by a high debt-to-equity ratio of 2.3, indicating a significant reliance on debt financing. With total liabilities of TWD 5,723,432,000 and total equity of TWD 1,559,435,000, the firm's leverage is well above the industry median. Liquidity is constrained, as evidenced by a current ratio of 0.83 and only TWD 66,091,000 in cash and equivalents. The negative net cash position after subtracting total debt further highlights the company's liquidity risk. Profitability metrics show a return on equity (ROE) of 9.97% and a return on assets (ROA) of 2.14%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming in terms of capital efficiency and asset utilization. The operating margin, calculated as operating income of TWD 211,257,000 on revenue of TWD 8,012,666,000, is 2.64%, which is also below the industry median. Geographically, the company is heavily concentrated in the domestic Taiwan market, with no disclosed international revenue streams. This concentration increases exposure to local economic and regulatory risks. The company's product mix is diversified across medical, health care, and biotech products, but the lack of segment-specific revenue data limits the ability to assess performance by business line. The company's growth trajectory is modest, with no disclosed revenue growth rate for the current fiscal year. The operating cash flow of TWD 903,967,000 and free cash flow of TWD 405,036,000 suggest some capacity for reinvestment or debt reduction, but the capital expenditure of TWD -279,553,000 indicates ongoing investment in infrastructure. The absence of a clear growth strategy or expansion plans in the latest filings raises questions about long-term sustainability. The risk assessment highlights medium liquidity risk and low dilution risk. The company's debt load and limited cash reserves increase the risk of liquidity stress, particularly in a high-interest-rate environment. No dilution risk is flagged, and the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent equity issuance. The absence of recent equity offerings or ATM facilities supports the low dilution risk rating. Recent events include the latest actual EPS of TWD 3.64 and revenue of TWD 8,012,666,000, as reported by analysts. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes. The company's focus remains on its domestic retail and hospital supply operations, with no new product launches or market expansions announced.